Experience with pegylated interferon α -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

Haematologica

Volumn 97, Issue 10, 2012, Pages 1570-1573

  Gowin, Krisstina ^a   Thapaliy, Prakash ^b   Samuelson, Jan ^c   Harrison, Claire ^d   Radia, Deepti ^d   Andreasson, Bjorn ^e   Mascarenhas, John ^f   Rambaldi, Alessandro ^g   Barbui, Tiziano ^g   Rea, Catherine J ^d   Camoriano, John ^b   Gentry, Amy ^b   Kiladjian, Jean Jacques ^h   O'Connell, Casey ^a   Mesa, Ruben ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e NU Hospital Organization   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g OSPEDALI RIUNITI   (Italy)

^h SAINT LOUIS HOSPITAL   (France)

Author keywords

Myeloproliferative neoplasms; Pegylated interferon alpha 2a; Response

Indexed keywords

ANAGRELIDE; HYDROXYUREA; PEGINTERFERON ALPHA2A;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CLINICAL TRIAL (TOPIC); COUGHING; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY (TOPIC); MYALGIA; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; PHLEBOTOMY; POLYCYTHEMIA VERA; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN ALLERGY; SPLENOMEGALY; STOMATITIS; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867261125     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.061390     Document Type: Article

References (13)

1. Bellucci S, Harousseau JL, Brice P, Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet. 1988;2(8617):960-1.
2. Barosi G, Liberato LN, Costa A, Ascari E. Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut. 1989;58(6): 271-4.
3. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418-24.
4. Ianotto JC, Kiladjian JJ, Demory JL, Roy L, Boyer F, Rey J, et al. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol. 2009;146(2):223-5.
5. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008; 112(8):3065-72.
6. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108(6):2037-40.
7. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and piprobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(4):417-21.
8. Barosi G, Birgegard G, Finazzi, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829-33.
9. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5):1497-503.
10. Barosi G, Bordessoule D, Briere J, Cervantes F, Demory JL, Dupriez B, et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood. 2005;106(8):2849-53.
11. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical Profile of homozygous Jak 2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840-6.
12. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007; 21(9):1952-9.
13. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009;124(4):409-17.